Table 2 Baseline characteristics of enrolled patients in each included study. Data are expressed as mean and standard deviation (SD) or frequency and percentage

P. Ambery et al. 2018 [6]

(MAD study)

MEDI0382 300 mcg

11

54.8 ± 6.8

7 (64%)

33.2 ± 4.2

99.7 ± 16.7

11 (100%)

0

0

0

placebo

19

57.7 ± 6

12 (63%)

31.2 ± 3.1

88.5 ± 11.4

19 (100%)

0

0

0

P. D. Ambery 2018 [15]

MEDI0382 300 mcg

6

28.3 ± 5.9

6 (100%)

27.4 ± 2.8

-

6 (100%)

0

0

0

placebo

12

32.8 ± 9.1

12 (100%)

25.7 ± 2.4

-

11 (91.7%)

0

0

0

Rajaa Nahra 2021 [16]

MEDI0382 300 mcg

256

56.3 ± 10.2

127 (94.6%)

-

-

252 (98.4%)

3 (1.2%)

1 (0.4%)

0

placebo

112

57.3 ± 9.5

57 (50.9%)

-

-

107 (95.5%)

0

1 (0.9%)

3 (2.7%)

NCT03645421

MEDI0382 300 mcg

15

57.5 ± 9.2

13 (86.7%)

-

-

0

0

15 (100%)

0

placebo

16

60 ± 8.6

13 (81%)

-

-

0

0

16 (100%)

0

NCT03596177

MEDI0382 300 mcg

19

59.5 ± 8.4

18 (94.7%)

-

-

18 (94.7%)

0

0

0

placebo

9

65.2 ± 7.2

7 (77.8%)

-

-

8 (88.9%)

1 (11.1%)

0

0

NCT03444584

MEDI0382 300 mcg

25

61 ± 8.2

15 (60%)

-

-

25 (100%)

0

0

0

placebo

24

58.4 ± 10

12 (50%)

-

-

24 (100%)

0

0

0

Parker 2020 [17]

Cohort 1

MEDI0382 300 mcg

26

58.7 ± 8.5

19 (73%)

31.5 ± 3.5

95.6 ± 17.2

25 (96%)

0

0

0

placebo

13

-

9 (69%)

31.6 ± 3.8

93.8 ± 21

13 (100%)

0

0

0

Cohort 2

MEDI0382 300 mcg

20

61.9 ± 6

10 (50%)

31.1 ± 3.5

92.4 ± 8.7

20 (100%)

0

0

0

placebo

6

-

5 (83%)

31.2 ± 3.5

93.7 ± 9.6

6 (100%)

0

0

0

NCT03550378

MEDI0382 300 mcg

21

71.1 ± 7.4

12 (57.1%)

-

-

20 (95.2%)

0

0

0

placebo

20

70.9 ± 4.7

9 (45%)

-

-

20 (100%)

0

0

0